Sajeva M R, Greco M M, Cascavilla N, D'Arena G, Scalzulli P, Melillo L, Minervini M M, Bonini A, Di Mauro L, Carotenuto M, Musto P
Division of Hematology, IRCCS Casa Sollievo della Sofferenza Hospital, S Giovanni Rotondo, Italy.
Bone Marrow Transplant. 1996 Jul;18(1):225-7.
We report a case of de novo plasma cell leukemia, resistant to standard VMD (vincristine, mitoxantrone, dexamethasone) and CVP (cyclophosphamide, vincristine and prednisone) protocols, treated with a chemotherapy intensification regimen (high-dose cyclophosphamide, modified EDAP, Dexa-BEAM) and peripheral blood stem cell transplantation, performed using fractionated total body irradiation and high dose melphalan. The patient is currently alive and well, in very good partial remission 12 months after transplant and 22 months after diagnosis, disclosing a significant proportion of bone marrow and peripheral blood CD3+, CD8+, CD57+, HLA-Dr+ large granular lymphocytes with cytotoxic activity against neoplastic plasma cells.
我们报告了一例原发性浆细胞白血病患者,该患者对标准的VMD(长春新碱、米托蒽醌、地塞米松)和CVP(环磷酰胺、长春新碱和泼尼松)方案耐药,接受了化疗强化方案(大剂量环磷酰胺、改良的EDAP、Dexa - BEAM)以及外周血干细胞移植治疗,移植采用分次全身照射和大剂量美法仑。该患者目前存活且状况良好,移植后12个月及诊断后22个月处于非常好的部分缓解状态,骨髓和外周血中可见相当比例的CD3 +、CD8 +、CD57 +、HLA - Dr +大颗粒淋巴细胞,这些细胞对肿瘤性浆细胞具有细胞毒活性。